The stock price of Passage Bio Inc (NASDAQ: PASG) has jumped by 402988 compared to previous close of 0.39. Despite this, the company has seen a fall of -14.37% in its stock price over the last five trading days. globenewswire.com reported 2025-06-23 that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Dose 2, 50% lower than Dose 1, substantially increased CSF PGRN levels at 30-days, reaching the upper limit of a healthy adult reference range Plan to amend upliFT-D protocol to include a prophylactic course of low dose anticoagulation and modify inclusion criteria to study patients earlier in disease progression Remain on track to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 PHILADELPHIA, June 23, 2025 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported updated data from the ongoing Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of frontotemporal dementia (FTD) with granulin (GRN) mutations and provided program updates and anticipated milestones. “We are pleased to share updated data highlighting the promise of PBFT02 for the frontotemporal dementia community.
Is It Worth Investing in Passage Bio Inc (NASDAQ: PASG) Right Now?
Moreover, the 36-month beta value for PASG is 1.70. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PASG is 52.62M and currently, short sellers hold a 3.43% of that float. On June 24, 2025, PASG’s average trading volume was 243.22K shares.
PASG’s Market Performance
The stock of Passage Bio Inc (PASG) has seen a -14.37% decrease in the past week, with a 11.23% rise in the past month, and a -33.19% fall in the past quarter. The volatility ratio for the week is 8.05%, and the volatility levels for the past 30 days are at 8.55% for PASG. The simple moving average for the past 20 days is -20.18% for PASG’s stock, with a -38.20% simple moving average for the past 200 days.
Analysts’ Opinion of PASG
Many brokerage firms have already submitted their reports for PASG stocks, with Wedbush repeating the rating for PASG by listing it as a “Outperform.” The predicted price for PASG in the upcoming period, according to Wedbush is $4 based on the research report published on November 29, 2024 of the previous year 2024.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see PASG reach a price target of $7. The rating they have provided for PASG stocks is “Buy” according to the report published on September 03rd, 2024.
PASG Trading at -8.80% from the 50-Day Moving Average
After a stumble in the market that brought PASG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -74.83% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PASG starting from ORBIMED ADVISORS LLC, who sale 89,328 shares at the price of $0.34 back on Apr 23 ’25. After this action, ORBIMED ADVISORS LLC now owns 6,718,195 shares of Passage Bio Inc, valued at $30,372 using the latest closing price.
ORBIMED ADVISORS LLC, the 10% Owner of Passage Bio Inc, sale 78,049 shares at $0.34 during a trade that took place back on Apr 22 ’25, which means that ORBIMED ADVISORS LLC is holding 6,807,523 shares at $26,537 based on the most recent closing price.
Stock Fundamentals for PASG
The total capital return value is set at -1.01. Equity return is now at value -83.73, with -56.03 for asset returns.
Based on Passage Bio Inc (PASG), the company’s capital structure generated 0.35 points at debt to capital in total, while cash flow to debt ratio is standing at -1.71.
Currently, EBITDA for the company is -61.69 million with net debt to EBITDA at 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.74.
Conclusion
To wrap up, the performance of Passage Bio Inc (PASG) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
